{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-004845","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2021-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.797380+00:00","generated_at":"2026-06-28T06:02:22.355354+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Enanta Pharma Q4 net loss $24.6M; FY net loss $79M; terminates HBV asset, plans COVID protease inhibitor","bullets":["Q4 revenue $23.6M (flat YoY); net loss $24.6M ($1.22 loss per diluted share) vs $29.3M loss a year ago.","FY revenue $97.1M (down 21% from $122.5M); net loss $79M ($3.92 loss per diluted share) vs $36.2M loss.","Terminated EDP-721 (HBV RNA destabilizer) due to adverse safety signals; positive Phase 1b data for EDP-514 HBV core inhibitor.","Plans to advance EDP-235 oral protease inhibitor for COVID-19 into Phase 1 in early 2022.","Discontinued internal NASH FXR agonist development; will pursue out-licensing; FY2022 guidance: R&D $150-170M, G&A $35-41M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-004845","json":"https://secwatch.observer/filing/0000950170-21-004845.json","markdown":"https://secwatch.observer/filing/0000950170-21-004845.md","text":"https://secwatch.observer/filing/0000950170-21-004845.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017021004845/0000950170-21-004845-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017021004845/enta-20211122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T06:02:22.355354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}